课题基金 / 基金详情

ANTI-CANCER PROTEOLYTIC ANTIBODIES

ANTI-CANCER PROTEOLYTIC ANTIBODIES
抗癌蛋白水解抗体
批准号：
6779630
负责人：
Vaughn Vasil Smider
金额：
$10.0万
依托单位：
INTEGRIGEN, INC.
依托单位国家：
美国
项目类别：
财政年份：
2004
资助国家：
美国
项目状态：
已结题
起止时间：
2004-04-01 至 2005-03-31
来源：
https://reporter.nih.gov/project-details/6779630
关键词：
antitumor antibodybacterial virusbioengineering /biomedical engineeringbiotechnologycombinatorial chemistrydrug design /synthesis /productiondrug screening /evaluationendopeptidasesmolecular probesneoplasm /cancer immunotherapyneutralizing antibodypeptide libraryphosphonatepolymerase chain reactionprotein bindingprotein engineeringrecombinant DNAvascular endothelial growth factors

项目摘要

项目成果

Vaughn Vasil Smider的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Antibody therapy is now common for several diseases. Some unique antibodies contain a protease function, with the ability to specifically degrade their target antigen. IntegriGen has cloned unique proteolytic antibody genes and will engineer them to bind and cleave therapeutically relevant target antigens. This project has three specific aims: 1) Clone and engineer libraries of proteolytic antibodies, 2) synthesize fluorophosphonate probes capable of specifically binding active proteases, and 3) screen the libraries of aim (1) against the model tumor antigen VEGF and the fluorophosphonate probe of aim (2) to discover new antigen specific proteolytic antibodies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Broadly neutralizing SARS-CoV-2 peptidic knobs
Ultralong CDR3 antibodies targeting exhausted T cells
Defining clinically relevant viral epitopes with cow antibodies
  • 批准号：
    9360293
  • 项目类别：
  • 资助金额：
    $37.98万
  • 财政年份：
    2017
  • 负责人：
    Vaughn Vasil Smider
  • 依托单位：
    SCRIPPS RESEARCH INSTITUTE, THE
Defining clinically relevant viral epitopes with cow antibodies
海外基金